Axogen, Inc. AXGN
We take great care to ensure that the data presented and summarized in this overview for Axogen, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXGN
View all-
First Light Asset Management, LLC Edina, MN4.09MShares$59.6 Million5.0% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$47.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.01MShares$43.8 Million3.58% of portfolio
-
Morgan Stanley New York, NY2.9MShares$42.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$35.3 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO2.28MShares$33.1 Million0.45% of portfolio
-
Assenagon Asset Management S.A.1.31MShares$19.1 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$14.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny960KShares$14 Million0.01% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA936KShares$13.6 Million3.37% of portfolio
Latest Institutional Activity in AXGN
Top Purchases
Top Sells
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Insider Transactions at AXGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 16
2024
|
Paul Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,875
+7.61%
|
-
|
Sep 13
2024
|
Erick Wayne De Vinney Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+1.37%
|
-
|
Sep 01
2024
|
Guido J Neels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+11.59%
|
-
|
Sep 01
2024
|
John Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+29.09%
|
-
|
Sep 01
2024
|
Alan M Levine Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+22.58%
|
-
|
Sep 01
2024
|
William P. Burke Mr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+29.42%
|
-
|
Sep 01
2024
|
Paul Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+27.08%
|
-
|
Sep 01
2024
|
Joseph A. Tyndall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+34.54%
|
-
|
Sep 01
2024
|
Amy Mc Bride Wendell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+10.37%
|
-
|
Jun 06
2024
|
John Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+38.37%
|
-
|
Jun 06
2024
|
William P. Burke Mr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+39.01%
|
-
|
Jun 06
2024
|
Amy Mc Bride Wendell Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+10.48%
|
-
|
Jun 06
2024
|
Alan M Levine Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+26.93%
|
-
|
Jun 06
2024
|
Paul Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+34.59%
|
-
|
Jun 06
2024
|
Kathy Johnson Weiler Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+50.0%
|
-
|
Jun 06
2024
|
Joseph A. Tyndall Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+50.0%
|
-
|
Jun 06
2024
|
Guido J Neels Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+11.89%
|
-
|
Jun 04
2024
|
Gregory Gene Freitag Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+4.03%
|
-
|
Mar 21
2024
|
Erick Wayne De Vinney Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
4,578
-0.87%
|
$32,046
$7.68 P/Share
|
Mar 21
2024
|
Karen L. Zaderej CEO |
SELL
Open market or private sale
|
Direct |
39,280
-1.13%
|
$274,960
$7.68 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 277K shares |
---|---|
Grant, award, or other acquisition | 441K shares |
Open market or private sale | 131K shares |
---|